← Leaderboards
Nikej Shah
Nirsum Laboratories, Inc.
$12,588,496
Attributed
$25,176,991
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.8M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,176,991 · 3
By mechanism
U01$9,732,775 · 1
UH3$9,160,866 · 1
UG3$6,283,350 · 1
Top collaborators
- Frank J. Vocci6 shared
- Mark Sorenson2 shared
Most similar at Nirsum Laboratories, Inc.
Same institution · by research overlap
- Mark Sorenson$4,866,388
Others in their field
Other Emerging Leaders on “Public Health”
- Kimberly Smith · Ppd Development Lp$115,671,664
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Mark Marino · Venturewell$51,488,542
- Susan M Landau · University Of California Berkeley$47,252,026
- Leonard Freedman · Leidos Biomedical Research, Inc.$39,554,144
Research focus
Public HealthRelapsePlasmaProdrugsOpioid Use DisorderRattusNalmefenePharmacodynamicsIntramuscularMu Opioid ReceptorsOpioid AbuseNovel TherapeuticsOpioid AntagonistOpioid EpidemicAbstinenceInjectionsAgonistInjectableBuprenorphineDoseMethadoneLegal PatentNaltrexoneSeverities
Grant awards (8)
Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder$4,947,774
U01 · FY2025 · DA · contact PI
Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder$4,785,001
U01 · FY2024 · DA · contact PI
Development of a novel drug for treating opioid use disorder$3,051,459
UH3 · FY2024 · DA · contact PI
Development of a novel drug for treating opioid use disorder$3,052,891
UH3 · FY2023 · DA · contact PI
Development of a novel drug for treating opioid use disorder$3,056,516
UH3 · FY2022 · DA · contact PI
Development of a novel drug for treating opioid use disorder$164,132
UG3 · FY2021 · DA · contact PI
Development of a novel drug for treating opioid use disorder$3,058,678
UG3 · FY2020 · DA · contact PI
Development of a novel drug for treating opioid use disorder$3,060,540
UG3 · FY2019 · DA · contact PI